The Impact of Osmotic Release Oral Delivery System Methylphenidate (OROS MPH) Upon Family of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD) - Trial 2015-001216-35
Access comprehensive clinical trial information for 2015-001216-35 through Pure Global AI's free database. This phase not specified trial is sponsored by Johnson & Johnson Taiwan Ltd and is currently status unknown. The study focuses on Attention Deficit Hyperactivity Disorder.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
2015-001216-35
Trial Details
EU Clinical Trials Register • 2015-001216-35
The Impact of Osmotic Release Oral Delivery System Methylphenidate (OROS MPH) Upon Family of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Study Focus
Sponsor & Location
Johnson & Johnson Taiwan Ltd
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
- Participants who cannot understand or follow the instructions given in the study
ICD-10 Classifications
Neurotic disorder, unspecified
Hyperkinetic disorder, unspecified
Hyperkinetic disorders
Disorder of brain, unspecified
Hyperkinetic conduct disorder
Data Source
EU Clinical Trials Register
2015-001216-35
Non-Device Trial